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the proportion of patients treated for RLS in a large claims data-
base. METHODS: We identiﬁed patients with at least one RLS
diagnosis (ICD-9 333.99) between 1999 and 2003 in Medstat’s
MarketScan Commercial Claims and Encounters database of de-
identiﬁed insurance claims from employees and dependents. We
estimated treated RLS by calculating the proportion of patients
in the database with a ﬁrst-time RLS diagnosis (incidence) and
with an RLS diagnosis anytime (prevalence). RESULTS: Inci-
dence of RLS treatment increased slightly each year, from 0.3402
per 1,000 persons in 1999 to 0.4494 per 1,000 in 2003. Preva-
lence also rose, reaching 0.5414 per 1,000 in 2003. Prevalence
rates per 1,000 in 2003 by age group were: ages 1–17, 0.0330;
ages 18–34, 0.1845; ages 35–44, 0.5848; ages 45–54, 1.0049;
and ages 55–64, 1.3069. Prevalence for women per 1,000 was
0.6576 compared to 0.4126 for men. US geographic regions with
the highest rates were North Central (0.6842) and South
(0.5686), with lower rates seen in Northeast (0.4074) and West
(0.4172). Higher rates of RLS (1.8621 vs. 0.3259 per 1000) were
found among patients who had any characteristic that put them
at “high risk” for RLS (anemia, end-stage renal disease, diabetes,
rheumatoid arthritis, pregnancy or SSRI use). CONCLUSIONS:
Rates of treated RLS were higher among older patients, women,
and those with “high risk” factors, consistent with previous
research. Compared to RLS prevalence estimates from popula-
tion-based studies, rates were low in our sample. Additional
research may help to understand the large differences in these
prevalence estimates.
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OBJECTIVES: Comparing length of stay by anticonvulsant
therapy may be the ﬁrst step to identifying adverse events asso-
ciated with treatment as well as treatment effectiveness. This
study attempts to determine the association between the hospi-
tal length of stay and the use of anticonvulsants by inpatients
with seizure disorders. METHODS: A cohort of 126,362
patients admitted to U.S. hospitals from July 1, 2004 to June 30,
2005 with a diagnosis of seizure or epilepsy was constructed
using data from Premier’s Perspective Comparative Database.
Anticonvulsant use was tracked throughout each patient’s 
hospital stay and patients were categorized by drug into carba-
mazepine, clonazepam, divaloprex, fosphenytoin, gabapentin,
lamotrigine, magnesium, oxcarbazepine, phenytoin, topiramate,
valproic acid, levetiracetam, and other anticonvulsants groups.
Descriptive statistics including demographic characteristics and
drug utilization were reported for the sample. Mixed regression
models were used to control for selection bias due to patient clus-
tering within hospitals. The model observed the impact of anti-
convulsant monotherapy by drug on length of stay. RESULTS:
Mean length of stay for non-users were 5.63 (SD = 9.02) and
drug users ranged between topiramate users with 5.42 (SD =
6.20) and magnesium users with 12.99 (SD = 18.27). Clon-
azepam (t = 5.41, p < 0.0001), divaloprex (t = 5.09, p < 0.0001),
gabapentin (t = 7.25, p < 0.0001), magnesium (t = 40.76, p <
0.0001) and phenytoin (t = 7.58, p < 0.0001) were signiﬁcantly
associated with length of stay while controlling for race, gender,
age, severity of illness and admission status. CONCLUSIONS:
Further analysis should investigate patterns of events associated
with increased length of stay in patients taking clonazepam,
divaloprex, gabapentin, magnesium, and phenytoin for identiﬁ-
cation of potential adverse events.
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OBJECTIVES: The oral prophylactic medications currently uti-
lized in the management of migraine headache have been shown
to exhibit varying responsiveness in terms of reduction of
headache burden. It is the objective of this model to be used as
tool to compare the relative cost-effectiveness (CE) of these
agents vs. botulinum toxin type A (BOTOX®/BTX-A) from a
payer perspective. METHODS: An interactive Excel-based
model was developed to compare the relative CE of the avail-
able oral prophylactic medications vs. BTX-A in the treatment
of migraine headache. Drug effectiveness with respect to reduc-
tion in headache burden and utilization of acute medications was
based on the published literature. Drug costs were based on
average wholesale price with consideration of contractual dis-
counts and patient co-payment. The primary economic end-
points were the drug cost per headache (HA) and headache day
(HAD) for episodic migraine and chronic migraine respectively.
Multi-factor sensitivity analyses were conducted. RESULTS: In
the management of episodic migraine, the oral prophylactic 
medications offered a cost per HA avoided varying from US$48
(divalproex sodium/Depakote®) to US$138 (gabapentin/
Neurontin®). In the management of chronic migraine, BTX-A
offered a cost per HAD avoided of US$17. Total migraine related
drug costs (inclusive of both acute and prophylactic medications)
were found to be unchanged with the utilization of BTX-A due
to the offsetting reduction in acute medication use associated
with BTX-A therapy. CONCLUSION: Modeling CE in terms of
reduction in headache burden provides a methodology for com-
paring clinical trials and demonstrates that the relative difference
in CE between the oral prophylactic medications and BTX-A in
the management of migraine headache is signiﬁcant.
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OBJECTIVES: Clinical trials establishing the efﬁcacy of disease
modifying drugs (DMDs) utilized in treating relapsing forms of
Multiple Sclerosis (MS) have been based on populations of
varying baseline relapse rates and disability burden. It is the
objective of this model to be used as a tool to compare the 
relative cost-effectiveness (CE) of these drugs from a payer 
perspective. METHODS: An interactive Excel-based model was
developed to compare the relative cost components of relapses,
disability progression, and DMDs in the treatment of MS. Drug
effectiveness with respect to reduction in relapses and the
slowing of disability progression was derived from the published
Level I clinical trial data and was based on absolute risk reduc-
tion (ARR) in clinical events to account for differences between
study populations. Cost data was based on work by O’Brien and
colleagues, and disability progression data was based on research
by Weinshenker and colleagues. Drug costs were based on
